Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis

BACKGROUND: The best investigational drug to treat cystic fibrosis (CF) patients with the most common CF-causing mutation (F508del) is VX-809 (lumacaftor) which recently succeeded in Phase III clinical trial in combination with ivacaftor. This corrector rescues F508del-CFTR from its abnormal intrace...

Descripción completa

Detalles Bibliográficos
Autores principales: Awatade, Nikhil T., Uliyakina, Inna, Farinha, Carlos M., Clarke, Luka A., Mendes, Karina, Solé, Amparo, Pastor, Juan, Ramos, Maria Margarida, Amaral, Margarida D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484512/
https://www.ncbi.nlm.nih.gov/pubmed/26137539
http://dx.doi.org/10.1016/j.ebiom.2014.12.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484512/
https://www.ncbi.nlm.nih.gov/pubmed/26137539
http://dx.doi.org/10.1016/j.ebiom.2014.12.005

Ejemplares similares